SCHEMBL19436623

SCHEMBL19436623

Cc1cc(N2CCC(F)(F)C2)nc2c(C(=O)O)cnn12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.53
GBA1 P04062 1/20 0.45
ALDH1A1 P00352 7/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 1/20 0.38
DPP4 P27487 1/20 0.37
HPGD P15428 6/20 0.37
HSD17B10 Q99714 4/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CACNA1H O95180 2/20 0.37
PDE10A Q9Y233 1/20 0.37
PTGER4 P35408 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19436786 0.93 KDM4E (0.51) KDM4EGBA1ALDH1A1SMN1; SMN2MAPT
SCHEMBL19436810 0.93 KDM4E (0.56) KDM4EGBA1ALDH1A1SMN1; SMN2MAPT
SCHEMBL19436681 0.87 KDM4E (0.53) KDM4EGBA1ALDH1A1SMN1; SMN2MAPT
SCHEMBL19455285 0.84 TYK2 (0.45) KDM4EGBA1ALDH1A1POLBNPC1
SCHEMBL19455573 0.84 GBA1 (0.42) GBA1DPP4CACNA1HPDE10A
SCHEMBL19455217 0.84 NTRK1 (0.43) KDM4EGBA1ALDH1A1POLBHPGD
SCHEMBL19436787 0.81 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL19436724 0.80 KDM4E (0.61) KDM4EGBA1ALDH1A1SMN1; SMN2MAPT
SCHEMBL19455323 0.80 ALDH1A1 (0.39) KDM4EGBA1ALDH1A1POLBHPGD
SCHEMBL19436661 0.80 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators Bial—R&D Investments, S.A. (PT) 2024-10-15 US disclosed
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2023-03-30 US disclosed
CN-109311887-B Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions BIAL研发投资股份有限公司 2022-09-13 CN disclosed
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-12-07 US disclosed
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders BIAL—BioTech Investments, Inc. (PT) 2021-03-02 US disclosed
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2019-10-31 US disclosed
EP-3440080-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-02-13 EP disclosed
US-9840510-B1 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2017-12-12 US disclosed
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2017-12-07 US disclosed
WO-2017176960-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators GBA1, GALC, GBA3 KDM4E 1067/4885GBA1 1/4885ALDH1A1 1260/4885
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, PARK7, GAA KDM4E 889/4885GBA1 1/4885ALDH1A1 1084/4885
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 KDM4E 690/4885GBA1 1/4885ALDH1A1 1104/4885
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 KDM4E 690/4885GBA1 1/4885ALDH1A1 1104/4885
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, GAA, PARK7 KDM4E 1447/4885GBA1 1/4885ALDH1A1 840/4885
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 KDM4E 690/4885GBA1 1/4885ALDH1A1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.